Interaction between beta-catenin and EGFR expression by immunohistochemistry identifies prognostic subgroups in early high-risk triple-negative breast cancer

Anticancer Research

Volumn 36, Issue 5, 2016, Pages 2365-2378

  Lakis, Sotirios ^a   Dimoudis, Stefanos ^a   Kotoula, Vassiliki ^a   Alexopoulou, Zoi ^b   Kostopoulos, Ioannis ^a   Koletsa, Triantafyllia ^a   Bobos, Mattheos ^a   Timotheadou, Eleni ^a   Papaspirou, Irene ^c   Efstratiou, Ioannis ^d   Aravantinos, Gerasimos ^e   Karavasilis, Vasilios ^a   Zagouri, Flora ^f   Gogas, Helen ^f   Razis, Evangelia ^g   Pentheroudakis, George ^h   Christodoulou, Christos ⁱ   Pectasides, Dimitrios ^j   Fountzilas, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Health Data Specialists Ltd   (Greece)

^c ALEXANDRA HOSPITAL   (Greece)

^d PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^e AGII ANARGIRI CANCER HOSPITAL   (Greece)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g HYGEIA HOSPITAL   (Greece)

^h UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

ⁱ METROPOLITAN HOSPITAL   (Greece)

^j HIPPOKRATION HOSPITAL   (Greece)

more..

Author keywords

Beta catenin immunohistochemistry; EGFR; EMT; Myc; Triple negative breast cancer (TNBC); Wnt pathway

Indexed keywords

BETA CATENIN; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; MYC PROTEIN; P CADHERIN; PARAFFIN; UVOMORULIN; EPIDERMAL GROWTH FACTOR; PROTEIN BINDING;

ADULT; ARTICLE; BASAL LIKE BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST CANCER; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

BETA CATENIN; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; PROTEIN BINDING; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85019094885     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO and Reis-Filho JS: Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24: 157-167, 2011.
2. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007.
3. Lawrence RT, Perez EM, Hernandez D, Miller CP, Haas KM, Irie HY, Lee SI, Blau CA and Villen J: The proteomic landscape of triple-negative breast cancer. Cell reports 11: 630-644, 2015.
4. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767, 2011.
5. Perou CM: Molecular stratification of triple-negative breast cancers. Oncologist 16(Suppl 1): 61-70, 2011.
6. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA and Perou CM: Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. The oncologist 18: 123-133, 2013.
7. Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortes J, Parker JS, Perou CM and Baselga J: Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. Journal of the National Cancer Institute 106 2014.
8. Yook JI, Li XY, Ota I, Hu C, Kim HS, Kim NH, Cha SY, Ryu JK, Choi YJ, Kim J, Fearon ER and Weiss SJ: A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol 8: 1398-1406, 2006.
9. Lu Z, Ghosh S, Wang Z and Hunter T: Down-regulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4: 499-515, 2003.
10. Bilir B, Kucuk O and Moreno CS: Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J Transl Med 11: 280, 2013.
11. Bienz M and Clevers H: Linking colorectal cancer to Wnt signaling. Cell 103: 311-320, 2000.
12. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512, 1998.
13. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R and Reis-Filho JS: beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 24: 209-231, 2011.
14. Lopez-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA, Sutherland RL and O'Toole SA: Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev 19: 301-309, 2010.
15. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI and Goss KH: Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176: 2911-2920, 2010.
16. Conacci-Sorrell M, Zhurinsky J and Ben-Ze'ev A: The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest 109: 987-991, 2002.
17. Ribeiro AS, Sousa B, Carreto L, Mendes N, Nobre AR, Ricardo S, Albergaria A, Cameselle-Teijeiro JF, Gerhard R, Soderberg O, Seruca R, Santos MA, Schmitt F and Paredes J: P-cadherin functional role is dependent on E-cadherin cellular context: a proof of concept using the breast cancer model. J Pathol 229: 705-718, 2013.
18. Bertocchi C, Vaman Rao M and Zaidel-Bar R: Regulation of adherens junction dynamics by phosphorylation switches. J Signal Transduct 2012: 125295, 2012.
19. Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, Pectasides D, Samantas E, Bafaloukos D, Stathopoulos GP, Karina M, Papadimitriou C, Skarlos D, Pisanidis N, Papakostas P, Markopoulos C, Tzorakoeleftherakis E, Dimitrakakis K, Makrantonakis P, Xiros N, Polichronis A, Varthalitis I, Karanikiotis C, Dimopoulos AM and Hellenic Cooperative Oncology G: Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol 19: 853-860, 2008.
20. Fountzilas G, Dafni U, Papadimitriou C, Timotheadou E, Gogas H, Eleftheraki AG, Xanthakis I, Christodoulou C, Koutras A, Papandreou CN, Papakostas P, Miliaras S, Markopoulos C, Dimitrakakis C, Korantzopoulos P, Karanikiotis C, Bafaloukos D, Kosmidis P, Samantas E, Varthalitis I, Pavlidis N, Pectasides D and Dimopoulos MA: Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC cancer 14: 515, 2014.
21. Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, Papadimitriou C, Markopoulos C, Polychronis A, Kalofonos HP, Siafaka V, Kosmidis P, Timotheadou E, Tsavdaridis D, Bafaloukos D, Papakostas P, Razis E, Makrantonakis P, Aravantinos G, Christodoulou C and Dimopoulos AM: Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 16: 1762-1771, 2005.
22. Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A and Dimopoulos MA: Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PloS one 7: e37946, 2012.
23. Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV and Fountzilas G: Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. Cancer Chemother Pharmacol 69: 533-546, 2012.
24. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC, American Society of Clinical Oncology and College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134: e48-72, 2010.
25. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology and College of American Pathologists: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31: 3997-4013, 2013.
26. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F and Schmitt FC: P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 11: 5869-5877, 2005.
27. Kashiwagi S, Yashiro M, Takashima T, Nomura S, Noda S, Kawajiri H, Ishikawa T, Wakasa K and Hirakawa K: Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer 103: 249-255, 2010.
28. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD and Ellis IO: Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15: 2302-2310, 2009.
29. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004.
30. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM and Statistics Subcommittee of the NCIEWGoCD: REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391, 2005.
31. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM and Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376, 2008.
32. Gelmon K, Dent R, Mackey JR, Laing K, McLeod D and Verma S: Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol 23: 2223-2234, 2012.
33. Choi J, Jung WH and Koo JS: Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. Histol Histopathol 27: 1481-1493, 2012.
34. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32, 2007.
35. Liu D, He J, Yuan Z, Wang S, Peng R, Shi Y, Teng X and Qin T: EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 29: 401-405, 2012.
36. Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, Veronesi P, Intra M, Torrisi R, Cardillo A, Campagnoli E, Goldhirsch A and Colleoni M: Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116: 317-328, 2009.
37. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM and Winer EP: TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 30: 2615-2623, 2012.
38. Chung GG, Zerkowski MP, Ocal IT, Dolled-Filhart M, Kang J Y, Psyrri A, Camp RL and Rimm DL: beta-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer 100: 2084-2092, 2004.
39. Hatsell S, Rowlands T, Hiremath M and Cowin P: Beta-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia 8: 145-158, 2003.
40. Hazan RB and Norton L: The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem 273: 9078-9084, 1998.
41. Martinez-Revollar G, Garay E, Martin-Tapia D, Nava P, Huerta M, Lopez-Bayghen E, Meraz-Cruz N, Segovia J and Gonzalez-Mariscal L: Heterogeneity between triple negative breast cancer cells due to differential activation of Wnt and PI3K/AKT pathways. Exp Cell Res 339: 67-80, 2015.
42. Liu N, Yu Q, Liu TJ, Gebreamlak EP, Wang SL, Zhang RJ, Zhang J and Niu Y: P-cadherin expression and basal-like subtype in breast cancers. Med Oncol 29: 2606-2612, 2012.
43. Ribeiro AS and Paredes J: P-Cadherin Linking Breast Cancer Stem Cells and Invasion: A Promising Marker to Identify an "Intermediate/Metastable" EMT State. Front Oncol 4: 371, 2015.
44. Xu J, Chen Y and Olopade OI: MYC and Breast Cancer. Genes Cancer 1: 629-640, 2010.